Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.

Inclusion Criteria: * Ages 18-40, no more than 10 years apart. * Both male and female. * Subjects have standard weight( generally not less than 50 kg), and body mass index (BMI) within 19-25. Subjects weight (kg) should not differ too much. * All physical examinations( including ECG, kidney function, liver function , blood routine, urine routines, etc) are normal. * History of disease: no history of diseases in gastrointestinal tract, reproductive tract, urinary tract, heart, liver, kidney, lung, nervous system, metabolism, and no history of allergies and orthostatic hypotension. * After being told all possible adverse reactions associated with the drug, subjects sign the informed consent and promise to complete all examinations. Exclusion Criteria: * Subjects who cannot communicate with medical staff, and subjects with cerebral insufficiency or psychological problem. * Female subjects or partner of male subjects have plan to pregnant. * Subjects have primary disease in significant organ. * Subjects have history of drug dependence or psychosis in last 2 years. * Subjects have blood loss or blood donation more than 200 mL 3 months prior to the baseline. * Subjects who have taken part in other clinical trials 3 months prior to the baseline. * Subjects who abuse alcohol or other drugs. * Pregnancy or breast-feeding subjects. * Subjects is found to have clinical significance of abnormal after checking information and physical examinations. * Known allergies or serious side effects with no more than two kinds of food and drugs in the past. * Subjects who have taken any drug during the previous 2 weeks. * Subjects have unexplained infections. * The subjects could not complete the study in the opinion of the Principal Investigator due to any reason. * Positive HIV、HCV and HBsAg test results. * A female subject whose pregnancy test is positive.